Trials / Completed
CompletedNCT00660309
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular filtration rate, and retinal blood flow in patients with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Aliskiren 300 mg tablets |
| DRUG | Irbesartan | Irbesartan 300 mg tablets |
| DRUG | Captopril | Captopril 25 mg tablet |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-04-17
- Last updated
- 2012-08-29
- Results posted
- 2012-08-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00660309. Inclusion in this directory is not an endorsement.